{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:34:56Z","timestamp":1793399696630,"version":"4.5.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1007\/s13730-020-00449-x","type":"journal-article","created":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T09:03:38Z","timestamp":1579683818000},"page":"173-176","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Rituximab-induced serum sickness in a 6-year-old boy with steroid-dependent nephrotic syndrome"],"prefix":"10.1007","volume":"9","author":[{"given":"Misako","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichiro","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chie","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiho","family":"Owada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kajiho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Harita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,22]]},"reference":[{"key":"449_CR1","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s10157-016-1313-5","volume":"21","author":"K Iijima","year":"2017","unstructured":"Iijima K, Sako M, Nozu K. Rituximab for nephrotic syndrome in children. Clin Exp Nephrol. 2017;21:193\u2013202.","journal-title":"Clin Exp Nephrol"},{"key":"449_CR2","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y, Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2014;384:1273\u201381.","journal-title":"Lancet"},{"key":"449_CR3","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.semarthrit.2015.06.014","volume":"45","author":"P Karmacharya","year":"2015","unstructured":"Karmacharya P, Poudel D, Pathak R, Donato A, Ghimire S, Giri S, Aryal M, Bingham C. Rituximab-induced serum sickness: a systematic review. Semin Arthritis Rheum. 2015;45:334\u201340.","journal-title":"Semin Arthritis Rheum"},{"key":"449_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s13730-017-0297-7","volume":"7","author":"R Maeda","year":"2018","unstructured":"Maeda R, Kawasaki Y, Ohara S, Suyama K, Hosoya M. Serum sickness with refractory nephrotic syndrome following treatment with rituximab. CEN Case Rep. 2018;7:69\u201372.","journal-title":"CEN Case Rep"},{"key":"449_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1093\/ckj\/sfx072","volume":"11","author":"J Cheong","year":"2018","unstructured":"Cheong J, Ooi K. Rituximab-induced serum sickness in the treatment of idiopathic membranous nephropathy. Clin Kidney J. 2018;11:51\u20133.","journal-title":"Clin Kidney J"},{"key":"449_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ejim.2019.06.009","volume":"67","author":"G Bayer","year":"2019","unstructured":"Bayer G, Agier MS, Lioger B, Lepelley M, Zenut M, Lanoue MC, Maillot F, Jonville-Bera AP. Rituximab-induced serum sickness is more frequent in autoimmune diseases as compared to hematological malignancies: a French nationwide study. Eur J Intern Med. 2019;67:59\u201364.","journal-title":"Eur J Intern Med"},{"key":"449_CR7","first-page":"430","volume":"34","author":"DJ Todd","year":"2007","unstructured":"Todd DJ, Helfgott SM. Serum sickness following treatment with rituximab. J Rheumatol. 2007;34:430\u20133.","journal-title":"J Rheumatol"},{"key":"449_CR8","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1002\/art.20430","volume":"50","author":"RJ Looney","year":"2004","unstructured":"Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab. Arthritis Rheum. 2004;50:2580\u20139.","journal-title":"Arthritis Rheum"},{"key":"449_CR9","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"JC Edwards","year":"2004","unstructured":"Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350:2572\u201381.","journal-title":"N Engl J Med"},{"key":"449_CR10","first-page":"967","volume":"26","author":"N Mehsen","year":"2008","unstructured":"Mehsen N, Yvon CM, Richez C, Schaeverbeke T. Serum sickness following a first rituximab infusion with no recurrence after the second one. Clin Exp Rheumatol. 2008;26:967.","journal-title":"Clin Exp Rheumatol"},{"key":"449_CR11","first-page":"771","volume":"57","author":"A Isoda","year":"2016","unstructured":"Isoda A, Ishikawa T, Sato N, Miyazawa Y, Matsumoto M, Sawamura M. Repeated rituximab-induced serum sickness with anaphylaxis. Rinsho Ketsueki. 2016;57:771\u20133.","journal-title":"Rinsho Ketsueki"},{"key":"449_CR12","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/ard.2006.057919","volume":"66","author":"R Seror","year":"2007","unstructured":"Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M, Candon S, Le Guern V, Aouba A, Sibilia J, Gottenberg JE, Mariette X. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sj\u00f6gren's syndrome. Ann Rheum Dis. 2007;66:351\u20137.","journal-title":"Ann Rheum Dis"},{"key":"449_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00467-016-3498-y","volume":"32","author":"M Vivarelli","year":"2017","unstructured":"Vivarelli M, Colucci M, Bonanni A, Verzani M, Serafinelli J, Emma F, Ghiggeri G. Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab. Pediatr Nephrol. 2017;32:181\u20134.","journal-title":"Pediatr Nephrol"},{"key":"449_CR14","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00467-017-3866-2","volume":"33","author":"S Fujinaga","year":"2018","unstructured":"Fujinaga S, Sakuraya K. Single infusion of low-dose ofatumumab in a child with complicated nephrotic syndrome with anti-rituximab antibodies. Pediatr Nephrol. 2018;33:527\u20138.","journal-title":"Pediatr Nephrol"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-020-00449-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13730-020-00449-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-020-00449-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,21]],"date-time":"2021-01-21T00:42:39Z","timestamp":1611189759000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13730-020-00449-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,22]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["449"],"URL":"https:\/\/doi.org\/10.1007\/s13730-020-00449-x","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,22]]},"assertion":[{"value":"13 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors have declared no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Informed consent was obtained from the patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}